Hebei Jiheng (Group) Pharmaceutical Co., Ltd

1、 Basic Overview of the Enterprise: Hebei Jiheng (Group) Pharmaceutical Co., Ltd. was established in 1996 with a registered capital of 38 million yuan and is a wholly-owned subsidiary of Hebei Jiheng Group. The company consists of two companies: API and formulation. The company covers an area of 500000 square meters and has a total asset of 706 million yuan. Its products include raw materials such as acetaminophen, analgin, aminopyrine, antipyrine, folic acid, water pills, tablets, DC granules, etc. It is a large-scale pharmaceutical comprehensive enterprise integrating research and development, production, and trade. Its leading products, acetaminophen and analgin, have obtained national GMP certificates, KOSHER certificates, Indian registration certificates, US DMF registration numbers, and HALAL certificates. The company has the right to independently import and export products, and its products are sold to more than 40 countries and regions in China, including the Middle East, Southeast Asia, South America, Eastern Europe, and Africa, in 30 provinces, cities, and autonomous regions. It enjoys a good reputation both domestically and internationally. The company has strong technical strength and owns the earliest provincial-level enterprise technology center in Hebei Province. It continuously strengthens communication and cooperation with domestic and foreign universities and research institutions, and has signed cooperation agreements with Shanghai Medical Research Institute, Hebei University of Science and Technology, Hebei University, Hebei University of Technology, and other higher education institutions to jointly organize and implement the high-tech achievement transformation project of cooperation between enterprises, research institutes, and universities, Enhanced the company's technological reserves and innovation capabilities. 2、 The proposed project technology needs to be introduced. Currently, the company has introduced one foreign expert, which has provided tremendous assistance for the transformation and upgrading of our existing production processes, as well as solving technical problems. Additionally, two members of the Royal New Zealand Academy of Sciences and three doctoral fellows can provide partial technical support for the company. In the later stage, talent treatment will be further improved, aiming to introduce more high-end foreign experts with years of work experience in pharmaceutical research and development, technology route synthesis, and other aspects. In terms of technical projects, the company will prioritize products that are pharmaceutical technology intensive, high value-added, widely used, and always in the low-end or blank stage of the domestic market, introduce superior technical talents, and break through technical barriers.